Detection and Assessment of Drug-Related Problems Associated with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Retrospective Cross-Sectional Study

Abstract

Background: Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a front-line therapy for type 2 diabetes mellitus (T2DM) with expanding indications including heart failure and chronic kidney disease. While its cardiorenal protective effects are well-established, the comprehensive profile of drug-related problems (DRPs) in real-world clinical settings requires further characterization.

Objective: To evaluate the drug-related problems associated with dapagliflozin therapy in patients with T2DM, including adverse drug reactions, drug-drug interactions, and side effect distribution across demographic subgroups.

Methods: A retrospective cross-sectional study was conducted over three months at Paalana Hospital, Palakkad. Nineteen patients (14 males, 5 females) aged ≥18 years with T2DM who had received SGLT2 inhibitors for at least six months were included. Data were collected using patient data entry forms, quality of life questionnaires, and WHO ADR reporting forms. Glycemic parameters (FBS, PPBS, RBS, HbA1c) were assessed at baseline, three months, and six months. Statistical analysis was performed using appropriate methods with significance set at p<0.05.